[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Qingdao Central Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":194},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,70,93,116,140,166],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100617758","phase-2-osimertinib-combined-with-savolitinib-in-the-treatment-of-nsclc-with-low-copy-number-met-amplification-100617758",false,"NCT07322783","Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification","Osimertinib Combined With Savolitinib in the Treatment of EGFR Mutated Osimertinib Resistant NSCLC With Low Copy Number MET Amplification","Inclusion Criteria:\n\n* 1\\. Histologically or cytologically confirmed incurable advanced or metastatic non-small cell lung cancer who resistant to resistant to osimertinib, chemo-immunotherapy or anti-angiogenesis.\n\n  2\\. At least 1 measurable lesion (RECIST 1.1). 3. MET amplification copy number below 5 by FISH. 4. Male or female patients age ≥18 years. 5. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2. 6. Estimated OS ≥3 months. 7. Adequate hematologic and bone marrow functions. 8. Adequate renal and liver function. 9. Had recovered from all toxicities related to prior anticancer therapies to grade ≤ 2, except for patients with grade 2 nausea\u002Fvomiting and\u002For grade 2 diarrhea despite optimal supportive therapy who will not be allowed to participate in the study.\n\n  10\\. Willingness to use contraception by a method that is deemed effective by the investigator by both males and female patients of child bearing potential (postmenopausal women must have been amenorrhea for at least 12 months to be considered of non-childbearing potential) and their partners throughout the treatment period and for at least three months following the last dose of study drug.\n\n  11\\. Ability to understand and willingness to sign a written informed consent form (the consent form must be signed by the patient prior to any study-specific procedures).\n\n  12\\. Willingness and ability to comply with study procedures and follow-up examination.\n\nExclusion13. Any of the following cardiac criteria: screening period resting period QTC \\> 470 milliseconds (clinical electrocardiograph report value; if a single time\\> 470 milliseconds, take the average of 3 inspections); rhythm of resting electrocardiogram (ECG), any clinically important abnormality of conduction or morphology (e.g., complete left bundle branch block, Grade 3 heart block, Grade 2 heart block); family history of congenital long QT prolongation syndrome or long QT syndrome.\n\n14\\. Evidence of any serious or uncontrolled systemic disease; various chronic active infections such as hepatitis B (HBV-DNA ≥ 104 copy number\u002Fml or 2000 IU\u002Fml), hepatitis C and HIV; uncontrollable Hypertensive patients (requires 2 or more drugs to control blood pressure); unstable angina; angina pectoris within 3 months prior to study; congestive heart failure (NYHA class II or higher); myocardial infarction (NSTEMI or STEMI) history in 6 months before study enrollment; severe arrhythmia requiring medical attention; severe liver, kidney, gastrointestinal or metabolic diseases.\n\n15\\. Patients who are unable to taking drugs 16. Other malignancies need treatment; except effectively treated skin basal cell carcinoma, cutaneous squamous cell carcinoma, and\u002For effectively resected orthotopic cervical cancer and\u002For breast cancer.\n\n17\\. Female patients during pregnancy or lactation. 18. Previous allergies or intolerance to treatment with osimertinib and savolitinib.\n\n19\\. Any other condition or circumstance of that would, in the opinion of the investigator, make the patient unsuitable for participation in the study.\n\nCriteria:\n\n\\-","ALL","18 Years","80 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Osimertinib combined with savolitinib in the treatment of EGFR mutated osimertinib resistant NSCLC with low copy number MET amplification There are unmet medical needs in patients who resist to to osimertinib; savolitinib plus osimertinib shows high response rate and prolong progression-free survival in high copy number MET amplification patients. This study is to explore the efficacy and safety of the combination of savolitinib and osimertinib in osimertinb resistant patients with low copy number MET amplification.",[27,28],"EGFR Positive Non-small Cell Lung Cancer","MET Amplification",[30,31,32],"Savolitinib","Osimertinib","Drug Resistant","RECRUITING","2025-12-29",{"date":36,"type":37},"2026-01-07","ACTUAL",{"date":39,"type":37},"2025-01-01",{"date":41,"type":21},"2026-12-31",{"name":43,"class":44},"Qingdao Central Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":45},"100599902","phase-2-bevacizumab-combined-with-cisplatin-versus-cisplatin-monotherapy-in-malignant-serous-effusions-100599902","NCT07090525","Bevacizumab Combined With Cisplatin Versus Cisplatin Monotherapy in Malignant Serous Effusions","Bevacizumab Combined With Cisplatin Versus Cisplatin Monotherapy in Malignant Serous Effusions-A Prospective Randomized Controlled Study","Inclusion Criteria:\n\n1. Voluntarily sign informed consent;\n2. Treatment naive serous effusion of patients with adenocarcinoma without activating gene mutation.\n3. Eastern Cooperative Oncology Group (ECOG) score ≤ 2;\n4. Survival is expected to exceed 3 months\n\nExclusion Criteria:\n\n* The subject had received anti-vascular endothelial growth factor (VEGF) small molecule tyrosine kinase inhibitors or monoclonal antibodies in the past 4 weeks; The subject had participated any clinical trials in the past 4 weeks; The subject had previously received bevacizumab of pleural perfusion therapy;\n\nLaboratory results:\n\nWhite blood cell count \\\u003C3 × 109 \u002F L, neutrophil count \\\u003C1.5 × 109 \u002F L, platelet \\\u003C75 × 109 \u002F L, or hemoglobin \\\u003C8g \u002F dL; Coagulation abnormalities (INR \\> 1.5 or prothrombin time (PT) \\> ULN + 4 seconds or activated partial thromboplastin time (APTT) \\> 1.5 ULN), with bleeding tendency or being treated with thrombolysis or anticoagulation; Serum total bilirubin ≥1.5 ULN; alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 2.5 ULN in the absence of liver metastases; ALT or AST ≥5 ULN in liver metastases; Serum albumin \\\u003C30g \u002F L; Serum creatinine ≥ 1.5 ULN or creatinine clearance \\\u003C40ml \u002F min; Urine routine urinary protein ≥ ++, or 24 hours urine protein ≥ 1.0 g; Hypertension cannot be controlled by drugs; Heart disease with significant clinical symptoms, such as: congestive heart failure, coronary heart disease with symptom, arrhythmia hardly be controlled by drugs, myocardial infarction in 6 months, or heart failure; Imaging (CT or MRI) showed a tumor lesion 5 mm away from the large vessels, or the presence of invasive central vasculature of the central tumor; imaging (CT or MRI) showed significant cavitation or necrosis of the lung tumor; Other diseases that may cause haemoptysis; Imaging (CT or chest radiograph) showed significant pneumothorax, fluid pneumothorax; Bilateral pleural cavity to a large number of effusion or encapsulated pleural effusion; Obvious cough blood in 6 months, or daily hemoptysis amounted to half a teaspoon (2.5ml) or more; Significant bleeding symptoms or with definite bleeding tendency within 12 months before randomization, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, occult blood ++ and above, intracerebral hemorrhage, vasculitis, or with congenital or acquired coagulopathy disorders; Thrombosis, cancer thrombosis (including arteriovenous thrombosis, tumor thrombus, pulmonary embolism, transient ischemic attack, etc.) occurred within 12 months; There are gastrointestinal obstruction, peptic ulcer, Crohn's disease, ulcerative colitis and other gastrointestinal diseases or other diseases may cause gastrointestinal bleeding or perforation; Severe respiratory diseases, or need long-term oxygen, corticosteroid treatment of diseases such as chronic obstructive pulmonary disease, interstitial lung disease and respiratory failure; The toxicity of previous antineoplastic therapies has not yet recovered to below grade 2 or has not fully recovered; Patients with uncontrolled central nervous system metastasis; There are serious uncontrolled systemic diseases, such as nephrotic syndrome, infection, poorly controlled diabetes; Patients with active HIV（human immunodeficiency virus）, HBV（hepatitis B virus）, or HCV（hepatitis C virus） infection; Patients had undergone surgery (\\\u003C28 days) or did not heal completely, or had other unhealed wounds before the study; Patients known to be allergic to bevacizumab or any of the components of the drug; Pregnant or lactating female patients, or unwilling to take contraceptive measures of reproductive age patients (including men); There is a serious psychological or mental abnormality, or lack of compliance; The investigator determines other circumstances that may affect the conduct of clinical studies and the determination of findings.",{"count":20,"type":21},[24],"The purpose of this study is to explore the efficacy and safety ofof bevacizumab plus cisplatin compare with cisplatin in the treatment of malignant serous effusion in patients with advanced adenocarcinoma",[57],"Overall Response Rate",[59,60,61],"Bevacizumab","malignant serous effusions","Randomized study","2025-07-21",{"date":64,"type":37},"2025-07-29",{"date":66,"type":37},"2025-07-01",{"date":68,"type":21},"2027-05-01",{"name":43,"class":44},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},"100526690","phase-2-sintilimab-and-chemotherapy-sequential-radiotherapy-in-advanced-esophageal-cancer-100526690","NCT06138028","Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer","The Prospective Study of Sintilimab Combination With Chemotherapy Sequential Radiotherapy for Advanced Esophageal Squamous Cell Carcinoma","Inclusion Criteria:\n\n1. Diagnosed with Stage IV esophagus squamous cell carcinoma.\n2. Expected survival time ≥3 months\n3. Enrolled patients must have at least one measurable lesion conforming to the RECIST V1.1 definition.\n4. Physical fitness ECOG score of 0 or 1\n5. Organ function levels must meet the following requirements and meet the following standards:\n\nA) Bone marrow function: absolute neutrophil count (ANC) ≥1.5×10\\^9\u002FL, platelet count ≥90×10\\^9\u002FL, hemoglobin ≥90 g\u002FL; B) Liver function: Total bilirubin TBIL≤1.5×ULN (total bilirubin ≤3×ULN in Subjects with Gilbert's syndrome, liver cancer or liver metastasis), AST and ALT ≤2.5×ULN in patients without liver metastasis, AST and ALT ≤5.0×ULN in patients with liver metastasis; C) Renal function: Creatinine (Cr) ≤1.5×ULN, or creatinine clearance (Ccr) ≥50 mL\u002Fmin (according to Cockcroft and Gault formula); D) Urine routine \u002F 24-hour protein quantification: qualitative urine protein ≤1+ (if qualitative urine protein ≥2+, 24 hours \\\u003C 1g can be included); E) Cardiac function: left ventricular ejection fraction ≥50%; F) Coagulation function: International standardized ratio (INR) ≤1.5×ULN, and activated partial thrombin time (APTT) ≤1.5×ULN;\n\nExclusion Criteria:\n\n1. Known or suspected history of active autoimmune diseases, autoimmune diseases (such as interstitial pneumonia, colitis, hepatitis, pituitaritis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases or syndromes)\n2. Have a history of immunodeficiency, including HIV positive, or other acquired, congenital immunodeficiency disease, or history of organ transplantation and bone marrow transplantation；Interstitial lung disease, drug-induced pneumonia,requiring steroid therapy or active pneumonia with clinical symptoms or severe pulmonary dysfunction；\n3. There are clinical symptoms or diseases of the heart that are not well controlled, such as: (1) heart failure of NYHA class 2 or higher (2) unstable angina (3) myocardial infarction within 24 weeks (4) clinical need for treatment or Interventional supraventricular or ventricular arrhythmia；\n4. Have a tendency to hereditary bleeding or coagulopathy. Clinically significant bleeding symptoms or clear bleeding tendency within 3 months prior to enrollment, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, baseline fecal occult blood++ and above；\n5. Allergic reactions to test drugs for this application；\n6. Pregnant or lactating women； Those whom the investigator considered unsuitable for inclusion。",{"count":78,"type":21},90,[24,80],"PHASE3","This is an investigator-initiated, single-arm, exploratory clinical study.The study population consisted of treatment naive advanced esophageal squamous cell carcinoma patients. The purpose of this study was to evaluate the efficacy and safety of immunotherapy combined with chemotherapy and residual lesions irradiation of esophageal squamous cell carcinoma.",[83],"Metastatic Esophageal Squamous Cell Carcinoma","2024-07-23",{"date":86,"type":37},"2024-07-24",{"date":88,"type":37},"2023-09-20",{"date":90,"type":21},"2026-10-31",{"name":43,"class":44},2,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":100,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},"100555594","chemoimmunotherapy-plus-residual-lesion-irradiation-for-the-treatment-of-extensive-stage-small-cell-lung-cancer-100555594","NCT06514118","Chemoimmunotherapy Plus Residual Lesion Irradiation for the Treatment of Extensive Stage Small-cell Lung Cancer","Chemoimmunotherapy Plus Ratiotherapy for Extensive Stage Small-cell Lung Cancer","Inclusion Criteria:\n\n\\>= 18 years of age Have an Eastern Cooperative Oncology Group (ECOG) performance status of =\\\u003C 1 at the time of study treatment initiation Histologically or cytologically confirmed diagnosis of small cell lung cancer (SCLC) Patient should have extensive stage disease, defined as, malignant pleural effusion, pulmonary metastases in the contralateral lung, and\u002For the presence of extra-thoracic metastatic disease Must have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 prior to starting platinum-based systemic chemotherapy Absolute neutrophil count (ANC) \\>= 1.5 x 10\\^9\u002FL Platelets \\>= 100 x 10\\^9\u002FL Hemoglobin \\>= 9 g\u002FdL Serum creatinine =\\\u003C 1.5 x institution upper limit of normal (ULN) and calculated creatinine clearance of at least 15 ml\u002Fmin.\n\nAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\\\u003C 3 x upper limit of normal (ULN) (ALT and AST =\\\u003C 5 x ULN is acceptable if liver metastases are present) Total serum bilirubin =\\\u003C 1.5 x ULN. For patients with well documented Gilbert's syndrome, total bilirubin =\\\u003C 3 x ULN with direct bilirubin within normal range.\n\nParticipant must understand the investigational nature of this study and sign an approved written informed consent form prior to receiving any study related procedure.\n\nExclusion Criteria:\n\n* ad major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered major surgery) resulting from a prior surgery Positive for immunosuppressive disease, acquired immunodeficiency syndrome (AIDS) or other immune depressing diseases. For human immunodeficiency virus (HIV), HVC and HBC-mandatory testing is required prior to enrollment Patient has known hypersensitivity to the components of the study drugs or any analogs History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, including, but not limited to: Myocardial infarction or arterial or venous thromboembolic events within 6 months prior to baseline or severe or unstable angina, New York Heart Association (NYHA) class III or IV disease. History of documented congestive heart failure (New York Heart Association functional classification III or IV) within 6 months prior to baseline. Poorly controlled arrhythmias",{"count":101,"type":21},70,"OBSERVATIONAL","This is a phase II trial studies the effect of chemoimmunotherapy sequential residual tumor irradiation in treating patients with extensive stage small cell lung cancer. Even though small cell lung cancer is initially highly responsive to first-line chemotherapy plus PD-L1 inhibitors, treatment resistance inevitably happens. Residual tumor irradiation my prolong drug resistance, and may help prevent the growth and spread of the tumor cells to other parts of the body.",[105,106,107],"Small-cell Lung Cancer","Residual Tumor","Radiation","2024-07-17",{"date":84,"type":37},{"date":111,"type":37},"2024-04-17",{"date":113,"type":21},"2027-03-16",{"name":43,"class":44},3,{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":123,"targetDuration":4,"studyType":22,"phases":125,"briefSummary":126,"conditions":127,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":45},"100554526","phase-3-nutrition-impact-on-immunotherapy-of-cancer-100554526","NCT06500234","Nutrition Impact on Immunotherapy of Cancer","Phase III Study on the Relation of Nutrition and Immunotherapy of Cancer Patients","Inclusion Criteria:\n\n* Diagnosis of cancer, malnutrition Age \\>18 years Performance status ECOG of 0 or 2. Life expectancy ≥ 6 months. At least one lesion measurable as defined by standard imaging criteria for the patient's tumor type (RECIST v1.1) Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment Postmenopausal or evidence of non-childbearing status for women of childbearing potential Patient is willing and able to comply with the protocol for the duration of the study.\n\nFor all oral medications patients must be able to comfortably swallow capsules;\n\nExclusion Criteria:\n\n* Patients unable to swallow orally administered medication and patients with Impairment of gastrointestinal (GI) function or GI disease that may significantly alter drug absorption of oral drugs History of allogenic organ, bone marrow or double umbilical cord blood transplantation.\n\nActive or prior documented autoimmune or inflammatory disorders Uncontrolled intercurrent illness or patient considered a poor medical risk due to a serious, uncontrolled medical disorder, including but not limited to, ongoing or active infection, symptomatic congestive heart failure Currently taking medications with known risk of prolonging the QT interval or inducing Torsades de Pointes.",{"count":124,"type":21},300,[80],"This study investigates nutritional status and outcomes of immuntherapy in cancer patients.",[128,129,130,131],"Nutrition Disorders","Immunotherapy","Cancer","Survival, Prosthesis","2024-07-12",{"date":134,"type":37},"2024-07-15",{"date":136,"type":37},"2024-06-01",{"date":138,"type":21},"2027-05-31",{"name":43,"class":44},{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":147,"sex":16,"minAge":17,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":22,"phases":151,"briefSummary":152,"conditions":153,"keywords":155,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":45},"100437330","phase-2-tyrosine-kinase-inhibitors-in-metastastic-adenoid-cystic-carcinoma-100437330","NCT04974866","Tyrosine Kinase Inhibitors in Metastastic Adenoid Cystic Carcinoma","Tyrosine Kinase Inhibitors in the Management of Local Advanced or Metastastic Adenoid Cystic Carcinoma","Inclusion Criteria:\n\n1. Histologically or cytologically confirmed adenoid cystic carcinoma\n2. Local, locally-advanced or metastatic disease documented as having shown progression on a scan (CT, MRI, MIBI scan) taken 2 to 12 months prior to baseline compared to a previous scan taken at any time in the past. Progression must be documented according to RECIST criteria.\n3. Disease that is not amenable to surgery, radiation or combined modality therapy with curative intent and who is previously treated with chemotherapy or local treatment (e,g transarterial chemoembolization)\n4. Presence of at least one measurable target lesion for further evaluation according to RECIST criteria\n5. 18 years or older\n6. ECOG performance status 0, 1, 2, 3\n7. Previous treatment with chemotherapy, loco-regional therapy (e.g chemoembolization) are permitted providing that toxicity has resolved to ≤grade 1 at study entry and that last treatment was at least 4 weeks prior to baseline assessment.\n8. Adequate organ function\n9. A patient with the willingness to comply with the study protocol during the study period and capable of complying with it\n10. A patient who signed the informed consent prior to the participation of the study and who understands that he\u002Fshe has a right to withdrawal from participation in the study at any time without any disadvantages.\n\nExclusion Criteria:\n\n* 1\\. A patient with no measurable disease, or allergy to the EGFR TKIs 2. Prior chemotherapy, radiation therapy or surgery within 4 weeks prior to study entry except palliative radiotherapy to non-target lesions (within 2 weeks prior to study entry) 4. A patient with intestinal obstruction or impending obstruction, recent active upper GI bleeding 5. A pregnant or lactating patient 6. A patient of childbearing potential without being tested for pregnancy at baseline or with being tested for positive. (A postmenopausal woman with the amenorrhea period of at least 12 months or longer is considered to have non-childbearing potential) 7. A man or woman of childbearing potential who has no willingness to use a contraceptive measure during the study 9. A patient with history of uncontrolled seizures, central nervous system disorder or psychiatric disorders that are considered clinically significant by the investigator that would prohibit the understanding of informed consent or that may be considered to interfere with the compliance of the administration of the study medications.\n\n  10\\. A patient with clinically significant heart disease (e.g. congestive heart failure, symptomatic coronary artery diseases, cardiac arrhythmia, etc) or myocardial infarction within past 12 months.\n\n  11\\. Ongoing cardiac arrhythmia of grade ≥2, atrial fibrillation of any grade, or QTc interval\\>450msec for males or \\>470msec for female.\n\n  12\\. A patient with interstitial pneumonia or diffuse symptomatic fibrosis of the lungs",true,"90 Years",{"count":150,"type":21},20,[24],"There is no clinical study on epidermal growth factor receptor tyrosine kinase inhibitors has been systematically conducted in adenoid cystic carcinoma.\n\nThis is a phase II study EGFR TKIs in adenoid cystic carcinoma to evaluate its efficacy in this disease.",[154],"Carcinoma, Adenoid Cystic",[156,157],"Neoplasms, Glandular and Epithelial","Adenocarcinoma","2023-03-27",{"date":160,"type":37},"2023-03-29",{"date":162,"type":37},"2021-07-01",{"date":164,"type":21},"2026-07-31",{"name":43,"class":44},{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":16,"minAge":173,"maxAge":174,"enrollmentInfo":175,"targetDuration":4,"studyType":22,"phases":177,"briefSummary":178,"conditions":179,"keywords":181,"overallStatus":185,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":45},"100452727","phase-3-colchicine-use-for-primary-prevention-of-coronary-artery-disease-100452727","NCT05175274","Colchicine Use for Primary Prevention of Coronary Artery Disease","Colchicine Use for Primary Prevention in People at High Risk of Coronary Artery Disease","Inclusion Criteria:\n\n1\\. Males and females who have at least 3 risk factors for CAD. 2. GFR\\>90mmol\u002FL. 3 People are within 40-70 years old.4. Patients are not pre-diagnosed with CAD, which is defined by negative results of CT coronary angiography.\n\nExclusion Criteria:\n\n1\\. Patients with any pre-existing diagnosis of coronary artery disease.2.Other cardiovascular diseases such as peripheral vascular disease, congestive heart failure and cardiomyopathy.3.Cerebrovascular diseases such as cerebral thrombosis and cerebral hemorrhage. 4.Currently on treatment with colchicine.5.Patients who are known to be allergic to colchicine.6 Chronic symptomatic heart failure within the last year and known reduced ejection fraction (LVEF≤40 %), documented before recruitment.7.Severe hepatic impairment (Child-Pugh class C) at the time of inclusion into the trial.8.Any other non cardiovascular diseases, such as active malignancy requiring treatment at the time of screening or with a life expectancy of fewer than two years based on the investigator´s clinical judgment.","40 Years","70 Years",{"count":176,"type":21},6792,[80],"Colchicine has been widely used as an anti-gout medicine in the past decades. Some recent clinical trials have proved that low-dose colchicine can be used as a secondary prevention drug for coronary artery disease because of its anti-inflammatory mechanism. However, the effect on primary prevention has not been observed sufficiently. The objective of this study is to determine whether colchicine reduces the incidence of CAD in patients and its safety for long-term use.",[180],"Coronary Artery Disease",[182,183,184],"Coronary artery disease","primary prevention","adverse events","NOT_YET_RECRUITING","2022-03-06",{"date":188,"type":37},"2022-03-21",{"date":190,"type":21},"2022-12-06",{"date":192,"type":21},"2028-07-01",{"name":43,"class":44},""]